A Phase 1b/2a, First in Human Clinical Trial of NB1111 for the Treatment of Glaucoma
Phase of Trial: Phase I/II
Latest Information Update: 25 Mar 2019
Price : $35 *
At a glance
- Drugs NB-1111 (Primary)
- Indications Glaucoma
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Emerald Bioscience
- 25 Mar 2019 According to an Emerald Bioscience media release, the company has changed its corporate name from Nemus Bioscience, Inc. to Emerald Bioscience, Inc.
- 14 Feb 2019 According to a NEMUS Bioscience media release, the company has signed an agreement with Pharmaceuticals International Inc. (Pii), a contract development manufacturing organization (CDMO) to develop a sterile eyedrop dosage formulation of NB1111 for human dosing.
- 15 Oct 2018 New trial record